Evidence map›Paper›PMID 35610366›Full record

Trial reportBritish journal of cancer2022

Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial.

Flora Zagouri, Georgia-Angeliki Koliou, Foteinos Dimitrakopoulos, Christos Papadimitriou, Ioannis Binas, Angelos Koutras, Pavlos Papakostas, Christos Markopoulos, Vasileios Venizelos, Grigorios Xepapadakis and 14 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 11 institutions in 2 countries.

Flora ZagouriDepartment of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece. florazagouri@yahoo.co.uk.ORCID http://orcid.org/0000-0001-7153-6556
Georgia-Angeliki KoliouSection of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, Athens, Greece.
Foteinos DimitrakopoulosDivision of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Patras, Greece.
Christos PapadimitriouDepartment of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
Ioannis BinasSecond Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
Angelos KoutrasDivision of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Patras, Greece.
Pavlos PapakostasDepartment of Medical Oncology, Hippokration Hospital, Athens, Greece.
Christos MarkopoulosSecond Department of Prop. Surgery, Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
Vasileios VenizelosBreast Unit, Metropolitan Hospital, Piraeus, Greece.
Grigorios XepapadakisBreast Unit, IASO, General Maternity and Gynecology Clinic, Athens, Greece.
Αngeliki AndrikopoulouDepartment of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
Charisios KaranikiotisDepartment of Medical Oncology, 424 Army General Hospital, Thessaloniki, Greece.
Amanda PsyrriSection of Medical Oncology, Department of Internal Medicine, Attikon University Hospital, Faculty of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
Dimitrios BafaloukosFirst Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
Paris KosmidisSecond Department of Medical Oncology, Hygeia Hospital, Athens, Greece.
Gerasimos AravantinosSecond Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.
Eleni ResThird Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.
Davide MauriDepartment of Medical Oncology, Medical School, University of Ioannina, Ioannina, Greece.
Anna KoumarianouHematology-Oncology Unit, Fourth Department of Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Kalliopi PetrakiPathology Department, Metropolitan Hospital, Piraeus, Greece.
Anna TsipouraPathology Department, Agii Anargiri Cancer Hospital, Athens, Greece.
Dimitrios PectasidesOncology Section, Second Department of Internal Medicine, Hippokratio" Hospital, Athens, Greece.
Helen GogasFirst Department of Medicine, Laiko General Hospital, University of Athens, Medical School, Athens, Greece.
George FountzilasLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
National and Kapodistrian University of Athens · GRMetropolitan Hospital · GRHospital Agioi Anargyroi · GRUniversity of Patras · GR424 General Military Hospital · GRAristotle University of Thessaloniki · GRHellenic Cooperative Oncology Group · GRHippocration General Hospital · GRHygeia Hospital · GRLETO Maternity Hospital · GRUniversity of Ioannina · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDose-dense sequential chemotherapy with anthracyclines and taxanes achieved an 18% reduction of recurrence risk in early breast cancer (BC). The optimal chemotherapy schedule and interval between cycles remain under investigation.

methodsOverall, 990 patients were randomised to receive either three cycles of epirubicin (E, 110 mg/m

resultsAt a median follow-up of 13.3 years, 330 disease-free survival (DFS) events (33.3%) were reported. DFS and overall survival (OS) did not differ between patients in the combined B and C arms versus arm A either in the entire cohort (HR = 0.90, P = 0.38 and HR = 0.85, P = 0.20) or among trastuzumab-treated patients (HR = 0.69, P = 0.13 and HR = 0.67, P = 0.13). Thirty-four patients (3.4%) developed secondary neoplasms.

conclusionsOverall, no significant differences in survival were found amongst the studied regimens after a long-term observational period.

trial registrationAustralian New Zealand Clinical Trials Registry ACTRN12610000151033.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsAustraliaChemotherapy, AdjuvantCyclophosphamideDisease-Free SurvivalEpirubicinFemaleFluorouracilHumansPaclitaxelTrastuzumabCyclophosphamideEpirubicinFluorouracilPaclitaxelTrastuzumab

Identifiers

PMID35610366
PMCPMC9381581
OpenAlexW4281400675

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.